According to our previous study, TRPV3 aggravates pathological myocardial hypertrophy through the calcineurin/NFATc3 pathway, promoting the extracellular Ca2+ flow and increases [Ca2+]i, and aggravates cardiac fibrosis through the TGF-β1 pathway (17,18). The gene discussed is NFATC3; the disease is cardiac hypertrophy.